MKI67 and neoplasm: Similarly, single cell spatial analysis from the NeoTRIPaPDL1 trial (NCT02620280) found that GATA3 and CD20 in the tumor microenvironment, HLA-DR on the epithelial cells, and Ki67 both on the tumor microenvironment and the epithelial cells, were significant for their predictive ability for atezolizumab benefit.